Phase Transitions Among of Valsartan Polymorphs due to Grinding and Humidity Variations

Yoga Windhu Wardhana, Risanteni Riskasari, Fikri Alatas

Abstract

Phase transition between drugs with polymorphisms needs attention due to unconscious changes in quality. Valsartan (VAL) is a drug model with polymorphic events to be studied here. Two polymorphic forms were obtained from recrystallization with various organic solvents such as acetonitrile and n-butyl acetate.  With untreated materials (from the market) were used as a comparison in this study. The phase transition of each polymorph was studied through grinding and humidity variations (RH 75% and 98%) treatment. The polymorph characterization was observed by microscope light polarization (PLM), Fourier Transform Infrared (FTIR), and Powdered X-ray Diffractometer (PXRD). The transition among polymorphic VAL was monitored by PXRD. There were significant differences in morphology, IR spectra, and diffractograms pattern. Found that the untreated VAL was amorphous, whereas the others were in high crystallinity. The polymorph form from n-butyl acetate was a metastable one that transformed easier into stable crystalline (from acetonitrile) than another polymorph.

Keywords : Valsartan, Phase transition, Polymorphism, Recrystallization    

Full Text:

PDF HTML

References

Ardianti F., Suciati IG. Profiles of Drug Substances, Excipients, and Related Me-thodology: Valsartan, 2015; 229–284.

Araya-sibaja AM, Paulino AS, Rauber GS, Campos CE, Cardoso SG, Monti GA, Heredia A, Bianco I, Beltrano D. and Cuffini SL. Dissolution Properties, Solid State Transformation and Polymor-phic Crystallization: Progresteronecase a study, Pharmaceutical Development Technology, 2014; 19(7): 779-778.

Lee AY, Erdemir D, Myerson AS. Crystal Polymorphism in Chemical Process Development, Annu Rev Chem Biomol Eng, 2011; 2: 259-280

Lin Shan–Yang, Cheng WT, Wang SL. Thermodynamic and Kinetic Characteri-zation of Polymorphic Transformation of Famotidine During Grinding. Int J Pharm, 2006; 318: 86–91.

Jensen DM, Eduardo C, Santos D, Souza RA, Denadai AML, Santos CFF, Braga ANG, and Rubén DS. Pharmaceutical Composition of Valsartan: β-Cyclo-dextrin: Physicochemical Characteriza-tion and Anti-Hypertensive Evaluation. Molecules, 2010; 15: 4067-4084.

Otsuka M, Ofusa T, Matsuda Y. Effect of Enviromental Humidity on the Transfor-mation Pathway of Carbamazepine Polymorphic Modification During Grinding. Colloids and Surfaces B. Biointerfaces, 1999; 13: 263–273.

Siddiqui N, Husain A, Chaudhry L, Alam MS, Mitra M, and Bhasin PS. Pharmacological and Pharmaceutical Profile of Valsartan: A Review. J Appl Pharm Sci, 2011: 01(04): 12–19.

Tran TTD, Tran PHL, Park JB, Lee BJ. Effect of Solvent and Crystallization Con-dition on the Polymorphic Behaviors and Dissolution Rates of Valsartan. Arch Pharm Res, 2012; 35(07): 1223–1230.

DOI: https://doi.org/10.24198/idjp.v3i2.35312

Refbacks

  • There are currently no refbacks.